Preliminary Program: Saturday May 17
8 a.m.-Noon
CME Courses 1-4
9 a.m.-4 p.m.
CME Courses 5-8
10 a.m.-5 p.m.
Registration/Course Enrollment Open
APA Resource Center Open
11 a.m.-5 p.m.
Publishers’ Bookfair Open
12:30 p.m.-3:30 p.m.
Industry-Supported Symposia
IS1. Schizophrenia Treatment in the Community: The Role of Long-Acting Antipsychotics Supported by Janssen Pharmaceutica
A. Key Issues in Long-Term Pharmacotherapy of Schizophrenia William T. Carpenter Jr., M.D.
B. The Latest Advance in Long-Acting Antipsychotic Therapy John M. Kane, M.D.
C. Translating From Clinical Trials to Community Care for Patients With Schizophrenia Jacqueline M. Feldman, M.D.
D. Overcoming Obstacles to Patient Acceptance of Long-Acting Antipsychotics David C. Henderson, M.D.
IS2. Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term Supported by GlaxoSmithKline
A. New Results From the Stanley Bipolar Treatment Network Robert M. Post, M.D.
B. Update on Anticonvulsants for Bipolar Disorders Charles L. Bowden, M.D.
C. Practical Strategies to Avoid Medication-Induced Mood Destabilization in Bipolar Patients Carlos M. Zarate Jr., M.D.
D. Psychosocial Strategies to Promote Stabilization and Enhance Coping in Patients with Bipolar Disorder David J. Miklowitz, M.D.
IS3. Anxiety Disorders: Sources, Signs, and Solutions Supported by Forest Laboratories Inc.
A. Examining Anxiety’s Underpinnings Christine Heim, Ph.D.
B. Anxious Body, Anxious Self, Anxious Psychiatrists Mack Lipkin, M.D.
C. Facing Up to Social Anxiety Disorder Murray B. Stein, M.D.
D. Generalized Anxiety Disorder: Beneath the Surface Jonathan R.T. Davidson, M.D.
E. The Neurobiology of Panic Disorder and OCD Stephen M. Stahl, M.D.
1 p.m.-5 p.m.
CME Courses 9-12
6 p.m.-9 p.m.
Industry-Supported Symposia
IS4. New Strategies for Managing Bipolar Disorder Supported by Janssen Pharmaceutica
A. Clinical Management of Bipolar Patients: A Difficult Task Dwight L. Evans, M.D.
B. Rational Polypharmacy in the Treatment of Patients With Bipolar Disorder S. Nassir Ghaemi, M.D.
C. Emerging Treatment for Bipolar Disorder: A New Role for Atypical Antipsychotics Lakshmi N. Yatham, M.D.
D. Complexities in the Treatment of Juvenile Bipolar Disorder Robert L. Findling, M.D.
IS5. Genetics and Psychiatry: Real Genes, Real Progress Supported by AstraZeneca Pharmaceuticals
A. Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants Rene Hen, Ph.D.
B. Recent Advances in Statistical and Gene-Finding Methods in Psychiatric Genetics Richard Straub, M.D.
C. Gene and Protein Expression in Brain: It Depends on Inheritance Joel E. Kleinman, M.D.
D. Rethinking the Concept of Phenotype in Psychiatry Robert Freedman, M.D.
E. In vivo Approaches to Identifying Genetic Mechanisms of Susceptibility Daniel R. Weinberger, M.D.
IS6. Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety Supported by Pfizer Inc.
A. Childhood Anxiety Disorders: Does Treatment Affect Long-Term Outcome? Moira A. Rynn, M.D.
B. The Burden of Anxiety Disorders David V. Sheehan, M.D.
C. Treatment for Generalized Anxiety Disorder: Current and Near Term Stuart A. Montgomery, M.D.
D. Future Directions: New Molecular Targets for the Treatment of Anxiety Jack M. Gorman, M.D.
IS7. Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia Supported by Eli Lilly and Company
A. Schizophrenia: New Understandings of the Early Stage of Illness Diana O. Perkins, M.D.
B. Improving Cognition for Quality Outcomes Richard S. Keefe, Ph.D.
C. Treatment Challenges for the Patient With Acute Agitation Leslie L. Citrome, M.D.
D. Metabolic Issues With Antipsychotic Therapy John B. Buse, M.D.
E. Maintenance Strategies: Balancing Efficacy and Safety to Prevent Relapse Thomas F. Liffick, M.D.
IS8. Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter? Supported by Forest Laboratories Inc.
A. The Alphabet Soup of Antidepressant Pharmacology: From TCAs and MAOIs to SSRIs, SNRIs, and Beyond Pedro L. Delgado, M.D.
B. SSRIs and Beyond: Spectrum of Efficacy of Newer Antidepressants Justine M. Kent, M.D.
C. Efficacy of Newer Antidepressants Michael E. Thase, M.D.
D. Generally Well Tolerated: Comparative Adverse-Event Profiles of Newer Antidepressants Andrew A. Nierenberg, M.D. ▪
Information & Authors
Information
Published In
History
Published online: 21 February 2003
Published in print: February 21, 2003
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).